vadimezan

DRUG3 trials

Sponsors

University of Glasgow, Swiss Cancer Institute, Novartis Pharmaceuticals

Conditions

Advanced or Recurrent Solid TumorsLung CancerUnspecified Adult Solid Tumor, Protocol Specific

Phase 1

Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors

CompletedNCT00003697

University of GlasgowUnspecified Adult Solid Tumor, Protocol Specific

Start: 1995-10-31End: 1998-12-31Target: 3Updated: 2013-12-19

Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors

CompletedNCT01285453

Novartis PharmaceuticalsAdvanced or Recurrent Solid Tumors

Start: 2009-03-31Updated: 2020-12-09

Phase 2

Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer

CompletedNCT01057342

Swiss Cancer InstituteLung Cancer

Start: 2010-01-31End: 2012-07-31Updated: 2013-04-10

Related Papers

The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors.

2011-08-1010 citations

Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.

2009-04-2212 citations